Navigation Links
Sanofi-aventis Obtains Antitrust Clearance in Connection With Chattem, Inc. Tender Offer
Date:1/26/2010

cation">New York (NYSE : SNY). For more information, visit: www.sanofi-aventis.us or www.sanofi-aventis.com.

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions.  Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or th
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc.
2. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
3. Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector
4. Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America
5. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
8. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
9. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
10. Sanofi-aventis Stands Behind the Safety of Lantus(R)
11. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... , Weltweite Exklusivlizenz ... ermöglicht QIAGEN die Entwicklung von Tests auf ... Blutkrebs  Neuer Test weist Mutationen ... Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf vermuten ...
(Date:7/24/2014)... July 24, 2014  IRIDEX Corporation (NASDAQ: ... second quarter 2014 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, July 31, 2014 ... other business developments. Interested parties may access ...
(Date:7/24/2014)... VANCOUVER, British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today ... the company,s fiscal year from December 31 to June 30. ... before September 30, 2014. Jeffrey Bacha , ... year end is an important step in achieving our goal ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
... SAN DIEGO, May 26, 2011 Volcano Corporation ... following statement: Earlier this year, the ... a wholly-owned subsidiary of St. Jude Medical, that ... misappropriated LightLab,s confidential information in connection for use ...
... YORK, May 26, 2011 A new prostate cancer ... Medicine comparing surgical treatment to "watchful waiting" ... cancer and currently debating their treatment options. ... the most commonly offered clinical options for early prostate ...
Cached Medicine Technology:Statement From Volcano Corporation on Latest St. Jude Lawsuit 2Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment 2Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment 3
(Date:7/25/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... Heather M. Young, PhD, RN, FAAN, of the ... of the Doris Schwartz Gerontological Nursing Research Award. ... Sciences Section, is given to a member of ... contribution to gerontological nursing research. , The award ...
(Date:7/25/2014)... by People Magazine in the article Mike 'The Situation' ... (7/15), one of the most popular cast stars from MTV's ... about his personal transformation. Now, two years later since the ... with his life was a challenge. He was previously addicted ... even spent some time in rehab. He took the opportunity ...
(Date:7/25/2014)... Merrill Corporation ( http://www.merrillcorp.com ), ... the financial, legal, healthcare and other corporate markets, ... Merrill DataSite, has been recognized as the “Technology ... the M&A Awards 2014 event. , ... management teams, advisors and financiers as they demonstrate ...
(Date:7/25/2014)... 2014 Ticket Down is a ... tickets in Berkeley at California Memorial Stadium. With the ... of football, the organizers of the 2014 Guinness International Champions ... to North America. With teams representing La Liga, English Premier ... some of the best football players from around the world ...
(Date:7/25/2014)... July 25, 2014(BRONX, NY)A study involving nearly 27,000 older ... 10 met criteria for pre-dementia based on a simple ... they have cognitive complaints. People who tested positive for ... dementia within 12 years. The study, led by scientists ... Yeshiva University and Montefiore Medical Center , was ...
Breaking Medicine News(10 mins):Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Slow walking speed and memory complaints can predict dementia 2Health News:Slow walking speed and memory complaints can predict dementia 3Health News:Slow walking speed and memory complaints can predict dementia 4
... us are counting,down the days leading up to the ... Council of America reminds you that time is running ... your flexible spending,account., Made available through employers, flexible ... pay for out-of-pocket health expenses,such as an eye exam ...
... CEO, Will Continue Serving as Chairman of the Board, ... Bulletin Board: MLSS), the recognized leader in,advanced injection technologies, ... Martin, Chief Executive Officer of the Company,s,medical division, as ... of its Board,of Directors, effective January 1, 2008. As ...
... A study led by Massachusetts General Hospital (MGH) researchers ... fibrosis (IPF), a usually fatal lung disease for which ... that a specific molecular pathway appears responsible for key ... IPF, the cause of which is currently unknown. ...
... has been shown to improve the sleep quality and ... most commonly-used medication, according to research published today in ... the effects of the new drug dexmedetomidine with the ... pain and anxiety experienced by mechanically ventilated ICU patients ...
... Philadelphia, PA, December 12, 2007 Major depressive disorder ... almost one in five individuals. More than 75% of ... have at least one recurrence, with the majority having ... disability of all medical illnesses, with substantial functional impairment, ...
... the fight against cancer: Recent research at the University ... Ganoderma lucidum aid in suppressing some of the mechanisms ... action of the fungus: disrupting androgen receptor activity and ... the past 3-4 decades much scientific research has dealt ...
Cached Medicine News:Health News:Joe Martin Appointed CEO of Milestone Scientific and New Executive Member of the Board of Directors 2Health News:Joe Martin Appointed CEO of Milestone Scientific and New Executive Member of the Board of Directors 3Health News:Molecular pathway appears crucial in development of pulmonary fibrosis 2Health News:Intensive care quality of sleep improved by new drug, reports study 2Health News:Venlafaxine extended-release effective for patients with major depression 2Health News:Active compounds found in Ganoderma lucidum fungus with potential to treat prostate cancer 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: